Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Nyxoah to Release First Quarter 2024 Financial Results on May 14, 2024
Nyxoah to Release First Quarter 2024 Financial Results on May 14, 2024Mont-Saint-Guibert, Belgium – May 13, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the first quarter 2024 on Tuesday, May 14, 2024, after market close...
Nasdaq GlobeNewswire
13/05/2024
Centessa Pharmaceuticals Reports Financial Results and Business Highlights…
Hemophilia Program: Ongoing registrational PRESent-2 and PRESent-3 studies of SerpinPC for the treatment of hemophilia B; PRESent-2 interim analysis planned in 2024 Orexin Agonist Program: Cleared IND and initiated Phase 1 first-in-human clinical trial of ORX750, a highly potent and selective OX2R agonist for the treatment of narcolepsy; Clinical proof-of-concept data in acutely sleep-deprived healthy volunteers planned in 2H of 2024 LockBody ®Technology Platform: Ongoing Phase...
Nasdaq GlobeNewswire
13/05/2024
Department of Health - Abu Dhabi Unveils 'Declaration of Principles' on…
The Declaration of Principles will witness leading local and global entities collaborate with DoH including Amazon, Microsoft, UAE University (UAEU), Mohammad Bin Zayed University for AI (MBZUAI), Core 42 and Masdar City. Segmented into six strategic pillars, the principles aim to advance Bioconvergence research and development, encourage investment in the field to address urgent healthcare challenges, establish international cooperation frameworks, prioritise research areas in public health and…
PR Newswire
13/05/2024
Veterinary Therapeutic Diet Sales Set to Total USD 3.8 Billion by 2034, Spurred…
Download the Sample PDF report to explore key market insights and trends: https://www.futuremarketinsights.com/reports/sample/rep-gb-19583 Download the Sample PDF report to explore key market insights and trends:https://www.futuremarketinsights.com/reports/sample/rep-gb-19583 Several factors are providing impetus for the growth of the veterinary therapeutic diet industry. These include high pet adoption, a rising focus on pet health, continuous innovation in the pet food sector, and a...
PR Newswire
13/05/2024
Oxurion Receives Transparency Notification from Atlas Special Opportunities…
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – May 13, 2024 – 07:00 PM CET(Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation 1it has received a transparency notification as follows: Oxurion received a transparency notification on May 9, 2024, from Atlas Special Opportunities, LLC indicating that as of May 2, 2024, it held 1,467,712,295...
Nasdaq GlobeNewswire
13/05/2024
Fagron shareholders approve all voting items at AGM and EGM
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 13 May 2024 – 7PM CET Fagron shareholders approve all voting items at AGM and EGM Fagron, the leading global player in pharmaceutical compounding, held its annual general meeting of shareholders and extraordinary general meeting of shareholders today. Both meetings approved all. voting items. ResolutionsThe annual general meeting approved, amongst other things, Fagron's annual financial statements and dividend...
Nasdaq GlobeNewswire
13/05/2024
AB Science announces issuance of a European patent for masitinib in the…
PRESS RELEASEAB SCIENCE ANNOUNCES ISSUANCE OF A EUROPEAN PATENT FOR MASITINIB IN THE TREATMENT OF SEVERE MASTOCYTOSIS WITH PROTECTION UNTIL 2036Paris, May 13, 2024, 6pm CETAB Science SA(Euronext - FR0010557264 - AB) today announced that the European patent office has issued a Grant Decision for a patent relating to methods of treating severe mastocytosis with its lead compound masitinib (patent EP 3359195A1). This new European patent provides intellectual property (IP)...
Nasdaq GlobeNewswire
13/05/2024
Evelyne Nguyen appointed EUROAPI's Chief Financial Officer
Press Release Paris – May 13, 2024 -Evelyne Nguyen has been appointed EUROAPI's Chief Financial Officer, effective May 14, 2024, and will be a member of the Executive Committee. She is taking over from Antoine Delcour, who is leaving the company to pursue new endeavors. Antoine will remain within the company until the end of June to ensure a smooth transition. “The entire company and the Board of Directors join me in expressing our sincere gratitude to Antoine for his...
Nasdaq GlobeNewswire
13/05/2024
Safe signs a strategic partnership in the United States with a californian…
Safe signs a strategic partnership in the United States with a californian hospital groupExpansion of presence in the United States, the leading spine marketFleurieux-sur-l'Arbresle-France – May 13, 2024 at 6 p.m. Safe SA (la « Société ») announces the signing of a SAFE solutions referencing contract with a group of American hospitals based in California, bringing together 3,000 affiliated doctors, in around thirty outpatient centers and clinics as well as around...
Nasdaq GlobeNewswire
13/05/2024
Novo Nordisk A/S: Once-weekly and once-monthly Mim8 demonstrate superior…
Bagsværd, Denmark, 13 May 2024– Novo Nordisk today announced the headline results from the FRONTIER 2 trial, a pivotal phase 3a, 26-week open-label, randomised, controlled, multi-arm trial in 254 people. The trial investigated the efficacy and safety of once-weekly and once-monthly subcutaneous Mim8 versus no prophylaxis and versus prior coagulation factor prophylaxis treatment in people aged 12 years or older with haemophilia A with or without inhibitors.The trial achieved its co-primary...
Nasdaq GlobeNewswire
13/05/2024
Medical Nutrition Market Size to Grow USD 88940 Million by 2030 at a CAGR of 6%…
Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-2Y9391/Global_Medical_Nutrition_Market Get Free Sample:https://reports.valuates.com/request/sample/QYRE-Auto-2Y9391/Global_Medical_Nutrition_Market Major Factors Driving the Growth of Medical Nutrition Market: The Medical Nutrition market is experiencing notable growth driven by several key factors. Firstly, there is a rising awareness among consumers regarding the importance of nutrition in managing various...
PR Newswire
13/05/2024
Clinical Lab Automation Market to be Worth $4.01 Billion by 2031 - Exclusive…
Clinical lab automation involves the utilization of automated devices and instruments in various procedures conducted in clinical laboratories or hospitals. This automation offers numerous advantages, including reduced human errors, cost savings, increased productivity, accelerated diagnostic speed, and improved efficiency in handling larger workloads without the need for a proportional increase in staffing. Clinical lab automation involves the utilization of automated devices and instruments...
PR Newswire
13/05/2024
Crystalline Fructose Market to Reach $1,198.6 million, Globally, by 2035 at 4.1%…
Download PDF Brochure: https://www.alliedmarketresearch.com/request-sample/A122334 Download PDF Brochure: https://www.alliedmarketresearch.com/request-sample/A122334 Prime Determinants of Growth The crystalline fructose market is assured for significant growth owing to several prime determinants. Firstly, the rising prevalence of lifestyle diseases like obesity, diabetes, and cardiovascular disorders has led to a surge in health consciousness among consumers. As a result, there is...
PR Newswire
13/05/2024
Biologics Safety Testing Market Worth $7.2 billion | MarketsandMarkets™
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=34624144 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=34624144 Browse in-depth TOC on "Biologics Safety Testing Market" 435 - Tables 64 - Figures 404 - Pages Biologics Safety Testing Market Scope: The services segment accounted for the largest share of the product & service segment in the biologics safety testing market in...
PR Newswire
13/05/2024
Transactions in Connection with Share Buy-back Program
Company Announcement COPENHAGEN, Denmark; May 13, 2024 – Genmab A/S (Nasdaq: GMAB).On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The share buy-back program is expected to be completed no later than December 16, 2024.The following transactions were executed under the program from May 6, 2024 to May 10, 2024: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)...
Nasdaq GlobeNewswire
13/05/2024
CathWorks Announces EU MDR Approval, Prominent Presence at EuroPCR and Full…
"The requirements of EU MDR are much more rigorous, sometimes compelling medical device manufacturers to rethink their commercialization strategy in Europe. We are very pleased to have successfully met the rigorous EU MDR requirements and believe this significant milestone underscores CathWorks' steadfast commitment to quality and patient safety. This approval is perfectly timed for the full European launch of our co-promotion partnership with Medtronic that will be in full display this…
PR Newswire
13/05/2024
Tendon Allograft Market to Reach $42.7 Billion Globally by 2032 at 5.2% CAGR…
Request Sample of the Report on Tendon Allograft Market Forecast - https://www.alliedmarketresearch.com/request-sample/A322367 Request Sample of the Report on Tendon Allograft Market Forecast -https://www.alliedmarketresearch.com/request-sample/A322367 Prime Determinants of Growth The rising prevalence of age-related conditions, such as tendon degeneration and tear among the aging population and the rising preference for minimally invasive procedures are the factors expected to...
PR Newswire
13/05/2024
King Faisal Specialist Hospital and Research Centre Welcomes New Deputy CEO Amid…
RIYADH, Saudi Arabia, May13, 2024(GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSH&RC) has recently welcomed Dr. Björn Zoéga as its Deputy CEO, an appointment that underscores its commitment to promoting and fostering healthcare excellence. Dr. Zoéga, renowned for his extensive experience in healthcare management and policy, joins a dedicated team as the hospital continues to drive key strategic initiatives. KFSH&RC, a leader in medical research...
Nasdaq GlobeNewswire
13/05/2024
SciBase announces outcome in the directed issue of units
Allotment of unitsAll units in the Directed Issue have been subscribed and the board of directors has therefore today, on 13 May 2024, resolved on allotment of units to Ribbskottet AB, Per Olof Ejendal AB, Kåre Gilstring, Robert Molander, MLJK Konsult AB, Klintemar Konsult AB, Jesper Hoiland, Fredrik Mattsson, Stefan Hansson, Ulti AB, Van Herk Investments B.V., Matt Leavitt, Viktor Drvota, Theodor Invest AB, and Eric Terhaerdt. Ribbskottet AB has chosen to subscribe for additional units in the…
PR Newswire
13/05/2024
Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22…
Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first quarter ended March 31, 2024, after U.S. markets close on Tuesday, May 21, 2024.Alvotech will also conduct a conference call with analysts to present the first quarter 2024 financial results and recent business highlights on Wednesday May 22, 2024, at 8:00 am EDT (12 noon GMT)...
Nasdaq GlobeNewswire
13/05/2024
Reneo Pharmaceuticals and OnKure Announce Proposed Merger
Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing OnKure's portfolio of novel precision medicines in oncology Combined company is expected to have approximately $120 million of cash resources at close, which is expected to provide funding through multiple clinical milestones and runway into fourth quarter of 2026IRVINE, Calif., and BOULDER, Colo., May13, 2024(GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM) and OnKure, Inc...
Nasdaq GlobeNewswire
13/05/2024
Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab
Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. [1]At present, 10 patients with na-SPMS have been dosed in an open-label intermediate-size Expanded Access (EA) Program with an additional 20 patients recently allowed to enter the program by the FDA. All patients in this expanded access program have either improved or stabilized on treatment with foralumab. 70% of patients have...
Nasdaq GlobeNewswire
13/05/2024
MolecuLight's Innovative Approach Awarded Best Abstract at EWMA 2024
The study upon which this abstract is founded was published earlier this year in the high-impact Diagnostics journal. Its findings underscore the undeniable correlation between the presence of fluorescence signals, detected by MolecuLight imaging devices, and poorer wound healing outcomes evidenced by poor wound area reduction. The study authors also yielded insightful revelations by comparing their manual measurement technique against digital measurement using the MolecuLight device. Manual…
PR Newswire
13/05/2024
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate…
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate UpdateLandmark deal announced with Takeda for ACI-24.060 with $100 million upfront and total potential payments for option exercise and milestones of up to approximately $2.1 billionACI-24.060 ABATE Phase 2 trial on track to report Abeta-PET imaging results in Q2 2024, evaluating amyloid plaque reduction after 6 months of anti-Abeta active immunotherapyACI-7104.056 VacSYn Phase 2 trial of anti-a-syn active...
Nasdaq GlobeNewswire
13/05/2024
Altri Comunicati
